Table 1. Subject Characteristics at Study Entry.
| Characteristic |
Risperidone (n=159) |
Olanzapine (n=48) |
Total (n=207) |
|||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | |
| Age (years) | 80.5 | 8.5 | 77.4 | 8.5a | 79.8 | 8.6 |
| Education (years) | 11.6 | 3.3 | 12.3 | 2.7 | 11.7 | 3.2 |
| Age at onset of neurological or psychiatric treatment (years) | 76.4 | 11.4 | 74.2 | 9.8 | 75.9 | 11.1 |
| Total weeks of follow-up | 83.6 | 66.8 | 76.9 | 60.6 | 82.1 | 65.3 |
| |
n |
% |
n |
% |
n |
% |
| Sex | ||||||
| Male | 39 | 25 | 23 | 48b | 62 | 30 |
| Female | 120 | 75 | 25 | 52 | 145 | 70 |
| Race | ||||||
| White | 137 | 86 | 42 | 87 | 179 | 87 |
| Black | 14 | 9 | 3 | 6 | 17 | 8 |
| Hispanic | 5 | 3 | 3 | 6 | 8 | 4 |
| Other | 3 | 2 | 0 | 0 | 3 | 1 |
| Primary diagnosis (DSM-IV) | ||||||
| Alzheimer's dementia | 80 | 51 | 16 | 33 | 96 | 47 |
| Multi-infarct dementia | 21 | 13 | 5 | 10 | 26 | 13 |
| Organic delusional syndromes and other organic mental syndromes | 3 | 2 | 1 | 2 | 4 | 2 |
| Major mood disorder | 44 | 28 | 20 | 42 | 64 | 31 |
| Schizophrenia and other psychotic disorders | 3 | 2 | 1 | 2 | 4 | 2 |
| Anxiety disorders and other disorders | 7 | 4 | 5 | 10 | 12 | 6 |
| History of ECT | 14 | 9 | 4 | 8 | 18 | 9 |
| Prior psychotropic medication | ||||||
| Anxiolytic | 47 | 30 | 21 | 44 | 68 | 33 |
| Antidepressant | 76 | 48 | 28 | 58 | 104 | 50 |
| Hypnotic | 21 | 13 | 7 | 15 | 28 | 14 |
| Lithium | 4 | 3 | 4 | 8 | 8 | 4 |
| Stimulant | 4 | 3 | 0 | 0 | 4 | 2 |
| Anti-dementia | 12 | 8 | 6 | 12 | 18 | 9 |
| Anti-Parkinsonian | 8 | 5 | 1 | 2 | 9 | 4 |
| Extra-pyramidal signs within 31 days of treatment | 37 | 23 | 10 | 21 | 47 | 23 |
a
t=2.23, df=205, p=0.027 (risperidone vs olanzapine subjects).
b
Fisher's exact test, two-sided probability=0.044 (risperidone vs olanzapine subjects).
Cumulative Rate of TD for Elderly Subjects Treated with SGA Drugs.